Autoimmune disorders are generally characterized by the destruction of healthy cells by the body’s own immune system. Autoimmunity can affect different parts of the body, can range in severity, and underlies a variety of serious conditions including Type 1 Diabetes Mellitus, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus and others.
TetraGenetics is identifying and developing immunomodulators that target T cell activation to halt the autoimmune cascade that results in disease. Specifically we are targeting both the voltage-gated potassium channel Kv1.3 and the calcium activated potassium channel KCa3.1 that are involved in the regulation of T cell membrane potential, calcium signaling and activation.
Additionally, TetraGenetics is working to determine high-resolution structures of non-disclosed potassium channels by cryoEM.